Promise of mGluR2/3 activators in psychiatry.
Conn
P Jeffrey
PJ
Vanderbilt Program in Drug Discovery, Department of Pharmacology, Vanderbilt Medical Center, Nashville, TN, USA. jeff.conn@vanderbilt.edu
Jones
Carrie K
CK
D000818:Animals; D001008:Anxiety Disorders / Q000188:drug therapy; D001713:Biphenyl Compounds / Q000494:pharmacology; D016503:Drug Delivery Systems; D006801:Humans; D007189:Indans / Q000494:pharmacology; D001523:Mental Disorders / Q000188:drug therapy*; D011725:Pyridines / Q000494:pharmacology; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists*; D012559:Schizophrenia / Q000188:drug therapy; D013449:Sulfonamides / Q000494:pharmacology
D001713:Biphenyl Compounds; D007189:Indans; C476436:N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine; D011725:Pyridines; D018094:Receptors, Metabotropic Glutamate; D013449:Sulfonamides; C522461:biphenyl-indanone A; C108822:metabotropic glutamate receptor 2; C102718:metabotropic glutamate receptor 3